BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND LDH AND Prognosis
149 results:

  • 1. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
    Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
    Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab.
    Popović A; Petković I; Dimitrijevic A; Jović A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):86-91. PubMed ID: 38006368
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine.
    Mao M; Dian Y; Sun Y; Chen W; Zhu W; Deng G
    Front Cell Infect Microbiol; 2023; 13():1237277. PubMed ID: 37920449
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
    Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
    J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
    [TBL] [Abstract] [Full Text] [Related]  

  • 6.
    Huang X; Chen L; Sha T; Lin Y; Zeng R; Xu J; Chen S; Cai HH; Zhang J; Zhou H; Sun PH; Jiang X
    ACS Nano; 2023 Oct; 17(20):20073-20086. PubMed ID: 37792448
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Association between weight loss and death in patients with malignant melanoma: A retrospective study of 28 cases.
    Tanaka A; Miyazawa H; Yanagi T; Maeda T; Kitamura S; Ujiie H
    J Dermatol; 2024 Mar; 51(3):463-466. PubMed ID: 37753543
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
    Beypınar I; Sözel Y; Önder AH
    Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CD39 and ldhA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.
    Mallardo D; Fordellone M; White A; Ottaviano M; Sparano F; Bailey M; Facchini AB; Ong S; Maiolino P; Caracò C; Church S; Cavalcanti E; Warren S; Budillon A; Cesano A; Simeone E; Chiodini P; Ascierto PA
    J Transl Med; 2023 Sep; 21(1):610. PubMed ID: 37684649
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Outcomes in patients with
    Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
    Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
    Pelizzari G; Bertoli E; Buriolla S; Vitale MG; Basile D; Palmero L; Zara D; Iacono D; Andrea F; Pascoletti G; Bolzonello S; Garutti M; Fasola G; Puglisi F; Minisini AM
    Melanoma Res; 2023 Oct; 33(5):398-405. PubMed ID: 37402350
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
    Del Carpio LP; Algarra MA; Sabaté-Llobera A; Rodriguez-Vida A; Rossi-Seoane S; Ruiz S; Leiva D; Ramos E; Lladò L; Lorenzo D; Gutierrez C; Cortes-Romera M; Caminal JM; Piulats JM
    Cancer Med; 2023 Jul; 12(13):14062-14071. PubMed ID: 37211960
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy.
    Mirjačić Martinović K; Vuletić A; Tišma Miletić N; Matković S; Gavrilović D; Ninković A; Jurišić V; Babović N
    J Clin Pathol; 2024 Apr; 77(5):343-351. PubMed ID: 36754615
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
    Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y
    Front Immunol; 2022; 13():1083840. PubMed ID: 36618343
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
    Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
    Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
    [No Abstract]    [Full Text] [Related]  

  • 16. KCNQ1OT1 sponges miR-34a to promote malignant progression of malignant melanoma via upregulation of the STAT3/PD-L1 axis.
    Wang X; Ren Z; Xu Y; Gao X; Huang H; Zhu F
    Environ Toxicol; 2023 Feb; 38(2):368-380. PubMed ID: 36399467
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Clinical features and prognosis of cutaneous melanoma].
    Tian Y; Li MW; Liu QK; Kang H
    Zhonghua Zhong Liu Za Zhi; 2022 Oct; 44(10):1146-1154. PubMed ID: 36319462
    [No Abstract]    [Full Text] [Related]  

  • 18. The multiple roles of ldh in cancer.
    Claps G; Faouzi S; Quidville V; Chehade F; Shen S; Vagner S; Robert C
    Nat Rev Clin Oncol; 2022 Dec; 19(12):749-762. PubMed ID: 36207413
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
    Dutriaux C; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Saiag P
    Eur J Cancer; 2022 Nov; 175():254-262. PubMed ID: 36170791
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinical predictors of survival in real world practice in stage IV melanoma.
    Hu HP; Archer C; Yip D; Peters G
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1691. PubMed ID: 36161287
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.